March 17, 2015
ViiV Healthcare K.K. announced on March 16 that it received approval on the same day for Triumeq, a fixed-dose combination tablet containing dolutegravir, abacavir, and lamivudine for the treatment of HIV infection in Japan. Triumeq contains the integrase inhibitor dolutegravir...read more